Segment and Geographic Information (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended													12 Months Ended																																										3 Months Ended	12 Months Ended															3 Months Ended	12 Months Ended			3 Months Ended		12 Months Ended	3 Months Ended		12 Months Ended				3 Months Ended			12 Months Ended
	Jun. 30, 2012		Mar. 31, 2012		Dec. 31, 2011		Sep. 24, 2011		Jun. 25, 2011		Mar. 26, 2011	Dec. 25, 2010	Sep. 25, 2010	Jun. 30, 2012 segments	Jun. 25, 2011	Jun. 26, 2010	Jun. 30, 2012 Consumer Healthcare (CHC) [Member]	Jun. 25, 2011 Consumer Healthcare (CHC) [Member]	Jun. 26, 2010 Consumer Healthcare (CHC) [Member]	Jun. 30, 2012 Analgesics [Member]	Jun. 25, 2011 Analgesics [Member]	Jun. 26, 2010 Analgesics [Member]	Jun. 30, 2012 Cough/Cold [Member]	Jun. 25, 2011 Cough/Cold [Member]	Jun. 26, 2010 Cough/Cold [Member]	Jun. 30, 2012 Gastrointestinal [Member]	Jun. 25, 2011 Gastrointestinal [Member]	Jun. 26, 2010 Gastrointestinal [Member]	Jun. 30, 2012 Other CHC [Member]		Jun. 25, 2011 Other CHC [Member]		Jun. 26, 2010 Other CHC [Member]		Jun. 30, 2012 Nutritionals [Member]	Jun. 25, 2011 Nutritionals [Member]	Jun. 26, 2010 Nutritionals [Member]	Jun. 30, 2012 Generic prescription drugs [Member]	Jun. 25, 2011 Generic prescription drugs [Member]	Jun. 26, 2010 Generic prescription drugs [Member]	Jun. 30, 2012 Active pharmaceutical ingredients [Member]	Jun. 25, 2011 Active pharmaceutical ingredients [Member]	Jun. 26, 2010 Active pharmaceutical ingredients [Member]	Jun. 30, 2012 Pharaceutical and medical diagnostic products [Member]	Jun. 25, 2011 Pharaceutical and medical diagnostic products [Member]	Jun. 26, 2010 Pharaceutical and medical diagnostic products [Member]	Jun. 30, 2012 Infant Nutritionals [Member]	Jun. 25, 2011 Infant Nutritionals [Member]	Jun. 26, 2010 Infant Nutritionals [Member]	Jun. 30, 2012 Vitamins, Minerals, and Dietary Supplements [Member]	Jun. 25, 2011 Vitamins, Minerals, and Dietary Supplements [Member]	Jun. 26, 2010 Vitamins, Minerals, and Dietary Supplements [Member]	Jun. 30, 2012 Consumer Healthcare [Member]	Jun. 25, 2011 Consumer Healthcare [Member]	Jun. 26, 2010 Consumer Healthcare [Member]	Jun. 26, 2010 Nutritionals [Member]	Jun. 30, 2012 Nutritionals [Member]	Jun. 25, 2011 Nutritionals [Member]	Jun. 26, 2010 Nutritionals [Member]	Jun. 30, 2012 Rx Pharmaceuticals [Member]	Jun. 25, 2011 Rx Pharmaceuticals [Member]	Jun. 26, 2010 Rx Pharmaceuticals [Member]	Jun. 30, 2012 API [Member]	Jun. 25, 2011 API [Member]	Jun. 26, 2010 API [Member]	Jun. 30, 2012 All Other Segments [Member]	Jun. 25, 2011 All Other Segments [Member]	Jun. 26, 2010 All Other Segments [Member]	Jun. 30, 2012 Unallocated Amount to Segment [Member]	Jun. 25, 2011 Unallocated Amount to Segment [Member]	Jun. 26, 2010 Unallocated Amount to Segment [Member]	Jun. 26, 2010 Net Sales [Member] Customer Concentration Risk [Member]	Jun. 30, 2012 Net Sales [Member] Customer Concentration Risk [Member] customers	Jun. 25, 2011 Net Sales [Member] Customer Concentration Risk [Member] customers	Jun. 26, 2010 Net Sales [Member] Customer Concentration Risk [Member] customers	Mar. 31, 2012 FLORIDA [Member] Consumer Healthcare [Member]	Dec. 31, 2011 FLORIDA [Member] Consumer Healthcare [Member]	Jun. 30, 2012 FLORIDA [Member] Consumer Healthcare [Member]	Jun. 25, 2011 Outside United States [Member]	Jun. 26, 2010 Outside United States [Member]	Jun. 30, 2012 Outside United States [Member]	Jun. 30, 2012 ISRAEL [Member]	Jun. 25, 2011 ISRAEL [Member]	Jun. 26, 2010 ISRAEL [Member]	Jun. 26, 2010 PBM Holdings, Inc. [Member] Nutritionals [Member]	Jun. 26, 2010 Facility Closing [Member] GERMANY [Member] API [Member]	Mar. 27, 2010 Facility Closing [Member] GERMANY [Member] API [Member]	Jun. 26, 2010 Facility Closing [Member] GERMANY [Member] API [Member]
Segment Reporting Information [Line Items]
Number of reporting segments														4
Write-off of in-process research and development														$ 0	$ 0	$ 19,000
Restructuring charges														8,755	1,033	9,523																																								699																				1,674	7,081	1,033								2,049	(6,013)	8,824
Inventory step-up charges																																																						495														1,031																	9,402
Revenues generated outside the U.S.																																																																															585,648	469,639	613,726
Disclosure on Geographic Areas, Percent of Revenue from External Customers Attributed to Foreign Countries																																																																																		12.00%	13.00%	11.00%
Number of major customers																																																																									1	1	1
Concentration risk percentage																																																																								23.00%	20.00%	22.00%
Net sales	831,767	[1],[2]	778,017	[3]	838,170	[4]	725,295	[5]	704,629	[6]	691,563	717,515	641,322	3,173,249	2,755,029	2,268,150	1,815,788	1,684,938	1,573,749	452,286	454,679	396,308	447,234	345,992	311,457	402,431	410,940	420,943	513,837	[7]	473,327	[7]	445,041	[7]	501,026	503,349	259,275	617,389	343,717	237,569	165,782	155,717	139,980	73,264	67,308	57,577	352,698	341,344	72,648	148,328	162,005	186,627	1,815,788	1,684,938	1,573,749		501,026	503,349	259,275	617,389	343,717	237,569	165,782	155,717	139,980	73,264	67,308	57,577	0	0	0
Operating income														569,226	490,205	335,899																																					295,653	293,097	303,677		33,023	68,040	2,257	223,198	120,364	48,503	55,525	37,819	15,312	2,744	1,266	2,201	(40,917)	(30,381)	(36,051)
Operating income %														17.90%	17.80%	14.80%																																					16.30%	17.40%	19.30%		6.60%	13.50%	0.90%	36.20%	35.00%	20.40%	33.50%	24.30%	10.90%	3.70%	1.90%	3.80%	0.00%	0.00%	0.00%
Total assets	4,024,047								3,186,653					4,024,047	3,186,653	3,101,628																																					1,651,374	1,333,392	1,362,366	971,879	950,988	992,967	971,879	1,072,647	448,634	429,599	258,352	282,515	229,566	90,686	129,145	108,218	0	0	0
Capital expenditures														120,192	99,443	57,816																																					76,291	59,629	35,670		14,412	16,186	7,770	7,991	15,329	6,239	18,489	4,230	5,336	3,009	4,069	2,801	0	0	0
Property and equip, net	578,350								507,308					578,350	507,308	448,583																																					328,011	286,850	258,619	90,489	94,488	96,098	90,489	67,558	35,510	21,374	79,626	75,059	67,240	8,667	13,791	10,861	0	0	0								180,000		183,000	92,000
Depreciation/amortization														$ 135,323	$ 102,941	$ 72,721																																					$ 40,982	$ 37,655	$ 32,881		$ 39,007	$ 33,480	$ 9,337	$ 42,214	$ 17,686	$ 17,299	$ 9,310	$ 10,065	$ 9,588	$ 3,810	$ 4,055	$ 3,616	$ 0	$ 0	$ 0

[1] (6)Includes a gain on the disposition of the Israel Consumer Products business of $8,639.

[2] (5)Includes restructuring costs of $1,674 associated with the closing of the Company's Florida facility.

[3] (4)Includes restructuring costs of $7,081 associated with the closing of the Company's Florida facility.

[4] (3)Includes $600 of severance costs associated with the Paddock acquisition.

[5] (2)Includes a pre-tax charge to cost of sales of $27,179 associated with the step-up in value of inventory related to the Paddock acquisition and approximately $8,800 of acquisition-related and severance costs associated with the Paddock acquisition.

[6] (7)Includes restructuring costs of $1,033 associated with exiting one of the Company's product lines manufactured at its Florida facility.

[7] Other CHC consists primarily of feminine hygiene, diabetes care, dermatological care and other miscellaneous or otherwise uncategorized product lines and markets.